Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)

Nessun marchio registrato trovato per questo principio attivo.

Nessuna nota sugli alimenti registrata per questo principio attivo.

• ErenumabMODERATO

  L'assunzione di Erenumab insieme a Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) può aumentare il rischio o la gravità di effetti indesiderati.

  Vista per esperti

  The risk or severity of adverse effects can be increased when Erenumab is combined with Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated).

• TheophyllineMODERATO

  L'assunzione concomitante di Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) può aumentare la concentrazione sierica (nel sangue) di Theophylline.

  Vista per esperti

  The serum concentration of Theophylline can be increased when it is combined with Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated).

• 2-MethoxyethanolMINORE

  L'assunzione concomitante di 2-Methoxyethanol può ridurre l'efficacia di Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated).

  Vista per esperti

  The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with 2-Methoxyethanol.

• 9-(N-methyl-L-isoleucine)-cyclosporin AMINORE

  L'assunzione concomitante di 9-(N-methyl-L-isoleucine)-cyclosporin A può ridurre l'efficacia di Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated).

  Vista per esperti

  The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.

• AbataceptMINORE

  L'assunzione concomitante di Abatacept può ridurre l'efficacia di Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated).

  Vista per esperti

  The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Abatacept.

• AbetimusMINORE

  L'assunzione concomitante di Abetimus può ridurre l'efficacia di Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated).

  Vista per esperti

  The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Abetimus.

• ActeosideMINORE

  L'assunzione concomitante di Acteoside può ridurre l'efficacia di Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated).

  Vista per esperti

  The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Acteoside.

• AdalimumabMINORE

  L'assunzione concomitante di Adalimumab può ridurre l'efficacia di Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated).

  Vista per esperti

  The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Adalimumab.

• AfelimomabMINORE

  L'assunzione concomitante di Afelimomab può ridurre l'efficacia di Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated).

  Vista per esperti

  The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Afelimomab.

• AldesleukinMINORE

  L'assunzione concomitante di Aldesleukin può ridurre l'efficacia di Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated).

  Vista per esperti

  The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Aldesleukin.